The first phase II trial which examined the activity of pembrolizumab, a PD-1 inhibitor antibody, in NSCLC patients with untreated or progressing brain metastases showed a CNS response in the cohort with PD-L1 expression ≥1% (29.7%; 15.9–47.0). Here, CD274 is linked to non-small cell lung carcinoma.